Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Med Oncol. 2010 Jun;27(2):430-3. doi: 10.1007/s12032-009-9228-6. Epub 2009 May 12.

Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study.

Author information

  • 1Department of Oncology, Division of Cellular and Molecular Medicine, St George's University of London, 2nd Floor, Jenner Wing, London SW17 0RE, UK. w.liu@sgul.ac.uk

Abstract

The proportion of people surviving pancreatic cancer is extremely low, with just 10% of patients diagnosed with any stage of the disease living beyond 1 year and a 5-year relative survival rate of <5%. The lack of effective therapy is one the main reason for such a bleak outlook. Herein, we report on a patient with pancreatic adenocarcinoma and metastatic disease treated with a combination regimen of gemcitabine and lenalidomide, without major complications. We also present in vitro data that highlight a hyper-additive effect of the two drugs when used in combination. To date, 33 months after diagnosis, the patient remains well and continues in full-time employment.

PMID:
19434525
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Springer
    Loading ...
    Write to the Help Desk